Abstract
INTRODUCTION
Suppositories have been recognized as an alternative to the oral route in situations such as when the patient is comatose, unable to swallow or when the drug produces nausea or vomiting. In the light of this, efforts have been made in recent times to present a good number of drugs in suppository form 1, 2, 3, 4 . However, investigators have shown that the physical and release properties of many suppositories depend considerably on the physicochemical properties of the drug, suppository base and formulation adjuvants 1, 5, 6 and a lot of formulation work is therefore normally required to optimise the properties of suppository preparations.
In the case of metronidazole, which has also been presented in suppository form 2, 7, 8, 9 due to various factors, especially gastrointestinal disturbances and nausea when given orally 6, 7 , there have been reports of a lot of variability in drug release from different suppository formulations 2, 7 .
Thus, the present work was designed to investigate the effects of some formulation factors on the physical and release properties of metronidazole suppositories with a view to providing more information on the way to optimize the properties of the resulting suppositories. It was considered of interest to study the effects of different formulation adjuvants with different properties on the physical and release properties of metronidazole in witepsol and polyethylene glycol (PEG) suppository formulations.
MATERIALS AND METHODS

Materials
The materials used were metronidazole BP (Rhone Poulenc, France); Witepsol H15 and E75 (Huls AG, France); Polyethylene glycol, PEG 1500 and PEG 6000 (Merck, Germany); Tween 80 and sodium salicylate (Merck, Germany); and methylcellulose (Bufa B.V., Netherlands).
Preparation of suppositories
Suppositories (1g) containing 200mg of metronidazole each were prepared by the fusion method following a previously described method 2 using Witepsol H15, Witepsol E75, and blends of polyethylene glycol 1500 and 6000 (70%:30% and 30%:70%) to give PEG 2850 and PEG 4650, respectively. The appropriate quantity of each suppository base was melted on a water bath. Prior to incorporation, metronidazole powder was passed through a 100 µm mesh sieve. Sodium salicylate was micronised and also passed through the same sieve. Quantities corresponding to 200mg of the metronidazole powder with and without adjuvant were added with trituration, using displacement value calculations. Adjuvants (Tween 80, sodium salicylate or methylcellulose) were added in different concentrations of 1, 3, 5 or 10% w / w for Tween 80 or sodium salicylate, and 1,5,10 or 20% w / w for methylcellulose. Mixing was continued until a homogeneous mass was produced. The mass was poured into stainless steel moulds, allowed to cool and the suppositories removed. Suppositories were weighed and kept at room temperature for 24h after removal from the mould to allow for uniform solidification and crystal transformation. The prepared suppositories were wrapped in aluminium foil and stored in a dessicator in a refrigerator until needed.
Evaluation of physical properties of suppositories
The prepared suppositories were subjected to several physical tests. The ease of moulding of the suppositories was assessed by the setting time of the molten mass, which was taken as the time for the suppository to set in the mould 10 .
Solidification point was also determined 10 . The test suppository was melted in a test tube at 45 0 C. A thermometer was dipped inside the cooling mass and rotated mechanically. The temperature at which the mass first began to adhere to the thermometer was recorded as the solidification point 10 .
Melting range was determined using the ascending melting point method 10 . Suppositories to be tested were melted in a water bath. One end of a straight capillary tube was dipped into the molten mass. The molten mass was allowed to rise to 5cm in the capillary tube and stored for 24h in the refrigerator. The capillary tube was then attached to a thermometer graduated in 0.20 increments and lowered into a water bath heated so that the temperature rose at the rate of 1 0 C per minute. The temperature at which the suppository began to melt and the temperature when clarification was observed were recorded as a range for the melting point.
The prepared suppositories were evaluated for uniformity of weight using twenty (20) suppositories for each formulation in accordance with the BP method 11 . Content uniformity was determined by spectrophotometric method. The suppositories were individually melted and dissolved in 100ml of phosphate buffer. After dilution, the absorbance was measured on a spectrophotometer (Pye Unicam, SP 6-550, Cambridge, England) at a wavelength of 275nm. It was established in preliminary experiments that the suppository bases and other materials did not interfere with absorbance measurement of metronidazole. The Erweka breaking strength tester (Erweka Apparatebau GmbH, Germany) was used to measure the resistance of the suppositories to crushing. All determinations were done in quadruplicate.
Evaluation of disintegration and release properties of the suppositories Disintegration time of the suppositories was determined 2 . The suppository to be tested was placed in a special glass container with perforated ends and immersed in a water bath maintained at 37 ± 1 0 C. A magnetic stirrer set at 100rpm was placed in the glass container. The time for disintegration was noted when the suppository has completely melted (Witepsol) or dissolved (PEG) in the medium.
In vitro release tests were carried out according to the USP XX basket method using the Hanson Easi-Lift dissolution equipment. Each suppository was placed in the basket 12 and lowered into a flask containing 500ml of phosphate buffer solution, pH 7.2, maintained at a constant temperature (37 ± 0.5 0 C). The basket was rotated at a constant speed of 50rpm. Samples (5 ml) were withdrawn at specified time intervals. Fresh buffer solution maintained at experimental temperature was used to replace the same volume of withdrawn samples.The amount of metronidazole in each sample was analysed spectophotometrically at 275nm (Pye Unicam, SP 6-550, Cambridge, England). The mean of four determinations was used to calculate drug release from each of the formulation.
The integrated form of the equation of Noyes and Whitney 13 , which has found wide application in describing the release kinetics of drugs from tablet dosage forms 14, 15, 16 is given below:
(1) Where C s is the concentration of the solute at saturation, C is its concentration at time t, and k is a dissolution rate constant. Adegboye and Itiola 2 have found this equation applicable to the release kinetics of suppository formulations. Kitazawa plots of ln[Cs/(Cs-C) ] versus t were constructed for all formulations 14 .
Statistical analysis
Results are expressed as the mean ± SD of four determinations. Analysis of variance (ANOVA) was used to test the statistical significance of differences among groups.
RESULTS
The results of all physical tests are presented in Table 1 . The results show that all prepared suppositories satisfied the BP requirement 11 for weight uniformity, with none of the individual weights deviating from the average by more than 5%. Also, the mean drug content for the suppositories was found to satisfy the BP requirement 11 for content uniformity for most suppository formulations.
None of the suppository formulations had less than 90% and none had more than 110% of expected metronidazole content. Table 2 , and both parameters also show ranking for the different bases which was the reverse of that for setting time: PEG 4650 > witepsol E75 > PEG 2850 > witepsol H15. The values of D T and t 80 decreased with increasing concentration of Tween 80 and sodium salicylate, but increased with methylcellulose. 
DISCUSSION
The physical and release properties of metronidazole suppositories were studied to provide more insights into the ways of optimizing the rectal formulation of the drug. The results obtained indicate that the prepared suppositories met official standards with regard to weight and content uniformity as presented in Table 1 . The results (Tables 1  and 2 ) also show that the physical and release properties of the suppositories were affected considerably by the formulation variables employed. The rankings of most of the physical and release parameters for the different suppository bases show that the bases can probably be employed to formulate metronidazole suppository formulations with a variety of physical and release properties for different purposes. The rankings also suggest that the values of most of the parameters increased with the ease with which the suppositories were moulded in the different bases as measured by the setting time.
The ranking of the dissolution rate constants was k 1 < k 2 < k 3 for relevant formulations (Table 2) , showing an increase in the rate of release of metronidazole with time. The t 1 values were found to decrease with increase in concentration of Tween 80 and sodium salicylate, but increased with increase in concentration of methylcellulose. The t 2 values (for formulations containing 5, 10 and 20% w / w methylcellulose) also increased with increase in methylcellulose content. Table 2 also shows that for all formulations, time t 1 was generally greater than the disintegration time, D T . Thus the disintegration time for the formulations did not correspond with the time for the change from k 1 to k 2 at t 1 , but rather D T occurred before t 1 . While this may be attributed to the greater agitation associated with the disintegration test 15 , it may also suggest that the melting/dissolving time of the suppository does not necessarily correspond exactly to the time of a change in dissolution rate. 
CONCLUSION
The study has shown that different physical properties and release rates can be obtained for metronidazole suppositories by using various bases and formulation adjuvants. Optimum concentrations of Tween 80 and sodium salicylate can be employed to formulate immediate-release suppositories. The results also suggest that methylcellulose can be used to formulate sustained-release metronidazole suppositories. Some insights into these inferences on release kinetics of the suppositories can be obtained from parameters derived from Kitazawa plots, and findings from the present work may be exploited in designing a rectal delivery system of metronidazole.
